Document is current
Any future updates will be listed below
-
Authors
Esposito, Daniela http://orcid.org/0000-0001-8993-2071
Tivesten, Åsa http://orcid.org/0000-0002-8318-0486
Olivius, Catharina
Ragnarsson, Oskar http://orcid.org/0000-0003-0204-9492
Johannsson, Gudmundur http://orcid.org/0000-0003-3484-8440
-
Funding
Funding for this research was provided by:
University of Gothenburg
- License Information
-
More Information
Article History
Accepted: 8 January 2024
First Online: 19 January 2024
Declarations
:
: D.E. has received lecture fees from Pfizer and Ipsen. O.R. has received lecture fees from Novo Nordisk, Ipsen, Sandoz, and Pfizer; an unrestricted research grant from HRA-Pharma; and consultancy fees from Novartis, Alnylam, Recordati Rare Diseases, and HRA-Pharma. G.J. has served as a consultant for Novo Nordisk, Shire, and Astra Zeneca; and has received lecture fees from Eli Lilly, Ipsen, Novartis, Novo Nordisk, Merck Serono, Otsuka, and Pfizer and unrestricted research grants from Novo Nordisk, Pfizer, and Shire. ÅT and C.O. declare no conflicts of interest.
